Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost‐savings
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16296 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Claire T Deakin und 8 weiteren Autor:innen. Beteiligte Einrichtung: OPAL Rheumatology Ltd, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Arthritis, Rheumatoid, Etanercept, Antirheumatic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Organon LLC, Merck Sharp & Dohme Corp., Merck Sharp and Dohme United Kingdom.
Abstract (Originalsprache)
Background and Aims This study aimed to assess the comparative effectiveness of the etanercept (ETN) originator (Enbrel) and ETN biosimilar SB4 (Brenzys) as first‐line treatment in patients with rheumatoid arthritis (RA), while also exploring the potential cost‐savings associated with this approach in Australia.
Methods
Clinical data were obtained from the Optimising Patient outcomes in rheumatoLogy Australian real‐world data set. Adult patients with RA who had initiated treatment with the ETN originator or biosimilar as their first‐recorded biologic or targeted synthetic disease‐modifying antirheumatic drug between 1 April 2017 and 31 December 2020 were included. Treatment persistence was analysed using survival analysis. Cost‐savings were estimated based on data reported by the Australian National Prescribing Service MedicineWise.
Results
Propensity score matching followed by inverse probability of treatment weighting selected patients taking originator ( n = 209) or biosimilar ( n = 141) with similar baseline characteristics and eliminated small differences in baseline disease activity. The median time for 50% of the patients to stop treatment was 19.4 months (95% confidence interval [CI], 14.7–36.4 months) for the originator and 22.4 months (95% CI, 15.0–33.1 months) for the biosimilar ( P = 0.95). As a result of pricing policies established by the Australian Government, introduction of the ETN biosimilar would have resulted in a cost‐savings of over AU$9.5 million for 1 year of treatment for the patients reported in this study.
Conclusion
Treatment persistence using either ETN originator or biosimilar was similar. The cost of all brands of ETN markedly reduced upon listing of the ETN biosimilar, resulting in significant savings for the Australian Government.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- OPAL Rheumatology Ltd, Sydney, New South Wales, Australia.
- Centre for Adolescent Rheumatology at University College London, University College London Hospitals and Great Ormond Street Hospital, London, UK.
- National Institute of Health Research Biomedical Centre at Great Ormond Street Hospital, London, UK.
- Department of Medicine, Monash University, Melbourne, Victoria, Australia.
- Barwon Rheumatology Service, Geelong, Victoria, Australia.
- Royal Melbourne Hospital, Melbourne, Victoria, Australia.
ORCID-Profile: Claire T Deakin, Geoffrey O Littlejohn, Hedley Griffiths, Catherine O'Sullivan, Tegan Smith, Peter Youssef, Paul Bird
Förderung
- Organon LLC
- Merck Sharp & Dohme Corp.
- Merck Sharp and Dohme United Kingdom
Zitieren
APA
Deakin, C. T., Littlejohn, G. O., Griffiths, H., Ciciriello, S., O'Sullivan, C., Smith, T., Youssef, P., Bird, P., & OPAL consortium (2024). Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost‐savings. Internal Medicine Journal. https://doi.org/10.1111/imj.16296
Vancouver
Deakin CT, Littlejohn GO, Griffiths H, Ciciriello S, O'Sullivan C, Smith T, et al. Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost‐savings. Internal Medicine Journal. 2024. doi:10.1111/imj.16296
BibTeX
@article{Deakin2024,
author = {Deakin, Claire T and Littlejohn, Geoffrey O and Griffiths, Hedley and Ciciriello, Sabina and O'Sullivan, Catherine and Smith, Tegan and Youssef, Peter and Bird, Paul and OPAL consortium, OPAL consortium},
title = {Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost‐savings},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16296}
}
EUVIMED